Delivery Order SPE2DR25D3103-SPE2DR26F9F74
- Not listed
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $2,148.10 to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Envarsus XR 1 mg tablets (100-count). This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 17, 2025, and represents a continuation of AmerisourceBergen's substantial pharmaceutical supply relationship with federal medical procurement. The work will be performed at the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Envarsus XR 4 mg tablets (100-count) under a firm fixed-price contract valued at $5,412.39, with an ultimate completion date of November 26, 2025. This non-set-aside award was competitively procured and represents a single delivery order within AmerisourceBergen's larger contract portfolio with DLA. The place of performance is listed as the company's corporate office in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,718.48 for 100 tablets of Envarsus XR 1 mg on July 28, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price, competitively awarded contract involves pharmaceutical delivery to support federal medical procurement needs. The contract does not include a set-aside designation and is being performed in Conshohocken, Pennsylvania, where AmerisourceBergen's corporate headquarters...
- The Defense Logistics Agency awarded a $1,718.48 delivery order to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 1 mg on September 24, 2025, with an ultimate completion date of October 16, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $3,000.80 on November 5, 2025, for the supply of Envarsus XR 4 mg tablets (100 count). The contract is a firm fixed-price delivery order with an ultimate completion date of November 28, 2025, and carries no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,581.30 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 1 mg tablets (100-count package) under a firm fixed-price contract. The order was competitively awarded without a set-aside designation and is scheduled for completion by September 15, 2025. AmerisourceBergen will fulfill this requirement from its corporate office location in Conshohocken, Pennsylvania, where the company is headquartered as a major...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on May 8, 2025, by the Defense Logistics Agency's Medical Supply Chain to supply Envarsus XR 1 mg tablets (30-count) at a ceiling value of $1,553.40. The contract is a firm fixed-price delivery order with an ultimate completion date of May 30, 2025, and was competitively awarded without set-aside designation. This award represents a child contract under...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Envarsus XR 0.75 mg tablets (30-count) with a ceiling value of $2,339.52. This delivery order represents a competitive, firm fixed-price procurement with no set-aside designation and is scheduled for ultimate completion by September 17, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $2,263.75 delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Envarsus XR 1 mg tablets in quantities of 100 units. This non-set-aside, competitively awarded contract carries a firm fixed price and is scheduled for completion by November 12, 2025. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on June 18, 2025, valued at $1,288.86 for the supply of Envarsus XR 1 mg tablets (100-count units) to the Department of Defense Medical Supply Chain. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 11, 2025. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DR25D3103Indefinite Delivery Contract
- SPE2DR25D3103-SPE2DR26F9F74Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,358.25 to supply Envarsus XR 1 mg tablets (100-count) with a firm fixed price and a completion date of December 8, 2025. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply framework with DLA. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and operates as a major pharmaceutical distributor supporting federal medical procurement needs. This delivery order is part of AmerisourceBergen's extensive engagement with the DLA Medical Supply Chain, through which the company fulfills pharmaceutical requirements across military and federal healthcare systems. AmerisourceBergen holds a significant Indefinite Delivery Contract valued at $999,999,999 with DLA Troop Support Medical (designation SPE2DX) extending through December 2026, which serves as the umbrella vehicle enabling the company to supply diverse pharmaceutical products and medical supplies globally. The company's federal contract portfolio demonstrates consistent capability in delivering specialized medications, including neurological treatments, diabetes medications, and pain management pharmaceuticals across multiple therapeutic domains to support military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 11/14/25 |